amitriptyline has been researched along with Fra(X) Syndrome in 1 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lacivita, E | 1 |
| Niso, M | 1 |
| Stama, ML | 1 |
| Arzuaga, A | 1 |
| Altamura, C | 1 |
| Costa, L | 1 |
| Desaphy, JF | 1 |
| Ragozzino, ME | 1 |
| Ciranna, L | 1 |
| Leopoldo, M | 1 |
1 other study available for amitriptyline and Fra(X) Syndrome
| Article | Year |
|---|---|
Privileged scaffold-based design to identify a novel drug-like 5-HT
Topics: Dose-Response Relationship, Drug; Drug Design; Fragile X Syndrome; HEK293 Cells; Humans; Molecular S | 2020 |